Gasparrini Silvia, Cimadamore Alessia, Mazzucchelli Roberta, Scarpelli Marina, Massari Francesco, Raspollini Maria Rosaria, Galosi Andrea B, Lopez-Beltran Antonio, Cheng Liang, Montironi Rodolfo
a Section of Pathological Anatomy , Marche Polytechnic University, School of Medicine, United Hospitals , Ancona , Italy.
b Division of Oncology , S. Orsola-Malpighi Hospital , Bologna , Italy.
Expert Rev Mol Diagn. 2017 Aug;17(8):781-789. doi: 10.1080/14737159.2017.1341314. Epub 2017 Jun 15.
Treatment planning in patients with prostate neoplasms and prostate cancer (PCa) is generally based on the clinical and pathological molecular markers obtained from prostate needle biopsy and/or radical prostatectomy specimens. Area covered: Pathology of prostate neoplasms is evolving rapidly. Emerging trends include new additions to the 2016 World Health Organization (WHO) tumor classification as well as expanded diagnostic utility of biomarkers and molecular testing in tissue specimens, liquid biopsies and urinary samples, with the following purposes: diagnosis, prognosis and prediction. Expert commentary: The new additions to the 2016 WHO tumor classification, which include pathological definition of Intraductal carcinoma of the prostate (IDC-P) and of a new grading system for PCa, as well as identification of molecular markers, such as TMPRSS2-ERG and AR-V7, may pave the way to personalized therapy for patients with prostate tumors.
前列腺肿瘤和前列腺癌（PCa）患者的治疗计划通常基于从前列腺穿刺活检和/或根治性前列腺切除术标本中获得的临床和病理分子标志物。涵盖领域：前列腺肿瘤的病理学正在迅速发展。新趋势包括2016年世界卫生组织（WHO）肿瘤分类中的新增内容，以及生物标志物和分子检测在组织标本、液体活检和尿液样本中的诊断效用扩展，目的如下：诊断、预后和预测。专家评论：2016年WHO肿瘤分类中的新增内容，包括前列腺导管内癌（IDC-P）的病理定义和PCa的新分级系统，以及分子标志物的鉴定，如TMPRSS2-ERG和AR-V7，可能为前列腺肿瘤患者的个性化治疗铺平道路。
